Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment

Thea Pharma

Status: Completed

Conditions: Dry Eye

Treatments: Device: Thealoz Duo

Study type: Observational

Funder types: Industry

Identifiers

NCT04803240

LT2280-PIV-0718

Details and patient eligibility

About

Multi-centre, international, non-interventional, prospective survey

Full description

To assess after 84 days, on a large scale patient population, the evaluation of ocular surface diseases and the satisfaction of dry eye disease (DED) treatment naïve patients or those who had to switch for tolerance, dissatisfaction or efficacy reasons to Thealoz® Duo.

Enrollment: 310 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All dry eye patients who require artificial tears or need to change their current artificial tears for any reason (i.e. due to dissatisfaction or low efficacy, etc...)
• Outpatients of either sex, aged at least 18 years
• Patients informed of the objectives of the survey and agreeing to participate.

Exclusion criteria

• Use of cyclosporine, lifitegrast, tacrolimus, sirolimus within last 3 months and during the survey

• Use of topical ophthalmological treatments (glaucoma, etc...)

• Use of lacrimal plugs

• Ocular surgery in the last 12 months

• Concomitant use of corticosteroids

• Concomitant use of autologous serum or any blood derivatives

• Severe blepharitis

• Severe dry eye associated to

  • Eyelid malposition
  • Corneal dystrophy
  • Ocular neoplasia
  • Sjogren syndrome
  • Any systemic pathologies

• Pregnancy/lactation